Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/43246
Title: | Search for Specific Biomarkers of IFNb Bioactivity in Patients with Multiple Sclerosis |
Author: | Malhotra, Sunny Bustamante, Marta F. Perez Miralles, Francisco Río, Jordi Ruiz de Villa, Carmen Vegas Lozano, Esteban Nonell, Lara Deisenhammer, Florian Fissolo, Nicolás Nurtdinov, Ramil N. Montalbán Gairín, Xavier Comabella, Manuel |
Keywords: | Esclerosi múltiple Marcadors bioquímics Multiple sclerosis Biochemical markers |
Issue Date: | 23-Aug-2011 |
Publisher: | Public Library of Science (PLoS) |
Abstract: | Myxovirus A (MxA), a protein encoded by the MX1 gene with antiviral activity, has proven to be a sensitive measure of IFNβ bioactivity in multiple sclerosis (MS). However, the use of MxA as a biomarker of IFNβ bioactivity has been criticized for the lack of evidence of its role on disease pathogenesis and the clinical response to IFNβ. Here, we aimed to identify specific biomarkers of IFNβ bioactivity in order to compare their gene expression induction by type I IFNs with the MxA, and to investigate their potential role in MS pathogenesis. Gene expression microarrays were performed in PBMC from MS patients who developed neutralizing antibodies (NAB) to IFNβ at 12 and/or 24 months of treatment and patients who remained NAB negative. Nine genes followed patterns in gene expression over time similar to the MX1, which was considered the gold standard gene, and were selected for further experiments: IFI6, IFI27, IFI44L, IFIT1, HERC5, LY6E, RSAD2, SIGLEC1, and USP18. In vitro experiments in PBMC from healthy controls revealed specific induction of selected biomarkers by IFNβ but not IFNγ, and several markers, in particular USP18 and HERC5, were shown to be significantly induced at lower IFNβ concentrations and more selective than the MX1 as biomarkers of IFNβ bioactivity. In addition, USP18 expression was deficient in MS patients compared with healthy controls (p = 0.0004). We propose specific biomarkers that may be considered in addition to the MxA to evaluate IFNβ bioactivity, and to further explore their implication in MS pathogenesis. |
Note: | Reproducció del document publicat a: http://dx.doi.org/10.1371/journal.pone.0023634 |
It is part of: | PLoS One, 2011, vol. 6, num. 8, p. e23634 |
URI: | http://hdl.handle.net/2445/43246 |
Related resource: | http://dx.doi.org/10.1371/journal.pone.0023634 |
ISSN: | 1932-6203 |
Appears in Collections: | Articles publicats en revistes (Genètica, Microbiologia i Estadística) Publicacions de projectes de recerca finançats per la UE |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
609649.pdf | 547.73 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License